



## PREVALENT DENGUE SEROTYPES IN CENTRAL, INDIA

|                            |   |
|----------------------------|---|
| <b>Dr. Shweta*</b>         | Tutor(M.D Microbiology), IGGMC Nagpur *Corresponding Author |
| <b>Dr. Sharmila Raut</b>   | Professor & Head, Microbiology Dept. IGGMC, Nagpur          |
| <b>Dr. Ravindra Khadse</b> | Associate Professor, IGGMC , Nagpur                         |
| <b>Ms Minal Bansod</b>     | Lab. Technician virology , IGGMC ,Nagpur                    |

**ABSTRACT** **Introduction:** Dengue is an endemic arbovirus disease, and ~3.9 billion peoples from more than 125 countries (accounting 40% of world population) are at risk. The dengue virus has four genetically distinct serotypes (DENV 1-4) that can cause either mild febrile flu-like symptoms, i.e., dengue fever or severe form called dengue hemorrhagic fever and dengue shock syndrome, which is characterized by vascular permeability and plasma leakage. **Methodology:** This was a cross-sectional study done from January 2019 to december 2021 at Department of Microbiology, I.G.G.M.C, Nagpur. The serum samples were then screened for the presence of dengue NS1 antigen, using Pan Bio NS1Ag ELISA kit. Laboratory confirmed NS1 positive acute phase serum samples, were sent to NIV Pune for serotyping within 72 hours of collection. All samples were transported on dry ice and they were tested by real time RT PCR at National Institute of Virology, Pune for dengue virus RNA & serotype identification. **Results:** out of total 283 suspected fever cases were subjected for the test NS1Ag ELISA of them, NS1Ag ELISA was found to be positive in 197 (69.61%) cases and out of total 197 NS1 ELISA positive cases were subjected for the test RT-PCR of them, RT-PCR was found to be positive in 108 (54.82%) cases. The most common serotype was found to be serotype DEN 1 followed by DEN 2 in both years. male preprodance of 61(56.48%) was found than females 47 (43.52%), In the year 2019-2020, maximum dengue positivity 9 (60%) was seen in the age group of 0-10 years while in the year 2020-2021, maximum positivity 52 (55.92%) was seen in the age group of 21-30 years. maximum positivity was found to be in the month of September followed by in October in both the years. **Conclusion:** The present study concluded that all four serotypes circulate with predominant being DENV-1 type. Dengue mainly affected adult male population, and seasonal peak during monsoon and post-monsoon period. The information of predominant serotypes can guide in forecasting dengue outbreaks and improving control measures of vectors thus may be helpful in the prevention of outbreaks.

**KEYWORDS :** Dengue virus, dengue virus-1, dengue virus-2, season, serotypes

### INTRODUCTION

Dengue virus causes dengue fever which is a febrile arboviral disease. It is an enveloped RNA virus with a single positive strand. It is transmitted through the bite of infected Aedes mosquito. The genome is composed of three structural protein genes, encoding the nucleocapsid or core protein (C), a membrane associated protein (M), an envelope protein (E), and seven non-structural (NS) protein genes. The non-structural (NS) proteins are NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 (WHO, 2014). NS1 is a highly conserved glycoprotein that seems to be essential for virus viability but has no established biological activity. There are four virus serotypes, which are designated as DENV 1, DENV 2, DENV 3 and DENV 4. Although all four serotypes are antigenically similar, they are different enough to elicit cross-protection only for a few months after infection by any one of them. Infection with any one serotype confers lifelong immunity to the virus serotype. (5) All four serotypes can cause the full spectrum of disease from a subclinical infection to a mild self-limiting disease, the dengue fever (DF) and a severe disease that may be fatal, the dengue haemorrhagic fever/dengue shock syndrome (DHF/ DSS). Immunity based antibody dependent enhancement (ADE) is one of the pathogenesis process, for the severe cause of the disease. (1)

Dengue is an endemic arbovirus disease, and ~3.9 billion peoples from more than 125 countries (accounting 40% of world population) are at risk. The dengue virus has four genetically distinct serotypes (DENV 1-4) that can cause either mild febrile flu-like symptoms, i.e., dengue fever (DF) or severe form called dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), which is characterized by vascular permeability and plasma leakage. In India, dengue poses an increasing burden with significant underreporting. Establishment of different serotypes and emergence of new genotype within serotypes which leads to enhanced disease severity due to the exacerbation of immune response mediated by Cytokines. (2)

Acute dengue can be diagnosed by detecting the DENV genome. A number of real-time RT-PCR assays have previously been developed, including a universal DENV real-time RT-PCR designed and validated methods detecting DENV genomes are recommended by the World Health Organization to be used for laboratory confirmation of dengue

during the first five to six days after symptomatic onset and PCR-based techniques are at present the only methods for determining the infecting serotype during acute disease.

The main aim and objectives of this study to find out the prevalent dengue serotype in the region.

### MATERIALS AND METHODS

This was a cross-sectional study done from January 2019 to december 2021 in the Department of Microbiology, I.G.G.M.C, Nagpur. The patients were evaluated by clinicians for dengue virus infection based on WHO 2009 criteria to identify patients suspected to have dengue. After informed consent, 3-5ml of blood samples from clinically suspected cases (who reported within one to five days of fever) were collected in a container without anti-coagulants. Patient history was taken on structured clinical data sheet provided by NIV, Pune. Serum was separated from the blood samples by centrifugation. The serum samples were then screened for the presence of dengue NS1 antigen, using Pan Bio NS1Ag ELISA kit and processed according to manufacturer's guidelines.

Laboratory confirmed NS1 positive acute phase serum samples, were sent to NIV Pune for serotyping within 72 hours of collection. Those serum samples which could not be processed within 72 hours of collection were stored in the deep freezer at -80 C until further processed. All samples were transported on dry ice and they were tested by real time RT PCR at National Institute of Virology, Pune for dengue virus RNA & serotype identification.

### RESULTS

**Table.1 DENGUE TEST POSITIVITY BY NS1 Ag ELISA :**

| Sr.no | Test     | NS1 Ag ELISA | Percentage % |
|-------|----------|--------------|--------------|
| 1.    | Positive | 197          | 69.61%       |
| 2.    | Negative | 86           | 30.39%       |
| 3.    | Total    | 283          | 100%         |

Total 283 suspected fever cases were subjected for the test NS1Ag ELISA of them, NS1Ag ELISA was found to be positive in 197 (69.61%) cases and 86 (30.39%) were negative.




Fig1: Dengue test positivity by NS1 Ag ELISA

Table.2 RT-PCR test results of NS1 positive samples :

| RT-PCR results | No of cases | Percentage % |
|----------------|-------------|--------------|
| Positive       | 108         | 54.82%       |
| Negative       | 89          | 45.18%       |
| Total          | 197         | 100%         |




Fig2: Dengue test positivity by RT-PCR test

Table.3 DISTRIBUTION OF SEROTYPES

| Sr. no | Serotypes | In The Year 2019-2020 | In The Year 2020-2021 | Total No.   |
|--------|-----------|-----------------------|-----------------------|-------------|
| 1.     | DEN 1     | 7 (46.67%)            | 44 (47.31%)           | 51 (47.22%) |
| 2.     | DEN 2     | 5 (33.33%)            | 37 (39.79%)           | 42 (38.89%) |
| 3      | DEN 3     | 3 (20%)               | 00                    | 3 (2.78%)   |
| 4.     | DEN 4     | 0                     | 12 (12.90%)           | 12 (11.11%) |
| 5      | TOTAL     | 15 (100%)             | 93 (100%)             | 108 (100%)  |




Fig 3 :- DISTRIBUTION OF SEROTYPES

Table 4: GENDER WISE DISTRIBUTION OF SEROTYPES

| Sr. no | Gender | Positive cases, n =108% |
|--------|--------|-------------------------|
| 1.     | Male   | 61(56.48%)              |
| 2.     | Female | 47 (43.52%)             |
| 3.     | Total  | 108 (100%)              |




Fig 4:- GENDER- WISE DISTRIBUTION

Table 5: GENDER- WISE DISTRIBUTION OF SEROTYPES:-

| Sr.no | Years     | Gender | Den 1       | Den 2       | Den 3      | Den 4     | Total       | Overall (108)% |
|-------|-----------|--------|-------------|-------------|------------|-----------|-------------|----------------|
| 1.    | 2019-2020 | Male   | 6 (40%)     | 4(26.6 6%)  | 2(13.3 3%) | 0         | 12 (80%)    | 15 (13.89%)    |
|       |           | Female | 1(6.66 %)   | 1(6.66 %)   | 1(6.66 %)  | 0         | 3 (20%)     |                |
| 2.    | 2020-2021 | Male   | 24(25. 80%) | 19(20. 43%) | 0          | 6(6.4 5%) | 49(52. 68%) | 93 (86.11%)    |
|       |           | Female | 21(22. 58%) | 16(17. 20%) | 0          | 7(7.5 2%) | 44(47. 31%) |                |




Fig 5: GENDER- WISE DISTRIBUTION OF SEROTYPES:-

Table 6:- AGE-WISE DISTRIBUTION in 2019-2020 and 2020-2021

| Sr.no | Age groups (years) | Positive cases (%) in 2019-2020 | Positive cases (%) in 2020- 2021 |
|-------|--------------------|---------------------------------|----------------------------------|
| 1.    | 0-10               | 9 (60%)                         | 24 (25.80%)                      |
| 2.    | 11-20              | 3 (20%)                         | 9 (9.68%)                        |
| 3.    | 21-30              | 2 (13.33%)                      | 52 (55.92%)                      |
| 4.    | 31-40              | 1 (6.67%)                       | 5 ( 5.37%)                       |
| 5.    | 41-50              | 0                               | 2 (2.16%)                        |
| 6.    | 51-60              | 0                               | 1 (1.07%)                        |
| 7.    | Total              | 15 (100%)                       | 93 (100%)                        |




Fig 6:- AGE-WISE DISTRIBUTION in 2019-2020 and 2020-2021

Table 7: AGE-WISE DISTRIBUTION OF DENGUE POSITIVE CASES BY RT-PCR

| Sr.No | Years     | Age groups | Den 1 | Den 2 | Den 3 | Den 4 | Total (108) % |
|-------|-----------|------------|-------|-------|-------|-------|---------------|
| 1.    | 2019-2020 | 0-10       | 1     | 7     | 1     | 0     | 9             |
|       |           | 11-20      | 1     | 1     | 1     | 0     | 3             |
|       |           | 21-30      | 0     | 2     | 0     | 0     | 2             |
|       |           | 31-40      | 1     | 0     | 0     | 0     | 1             |
|       |           | 41-50      | 0     | 0     | 0     | 0     | 0             |
|       |           | 51-60      | 0     | 0     | 0     | 0     | 0             |
|       |           | Total      |       |       |       | 15    |               |
| 2.    | 2020-2021 | 0-10       | 15    | 9     | 0     | 0     | 24            |
|       |           | 11-20      | 3     | 5     | 0     | 1     | 9             |
|       |           | 21-30      | 24    | 19    | 0     | 9     | 52            |
|       |           | 31-40      | 4     | 0     | 0     | 1     | 5             |
|       |           | 41-50      | 0     | 1     | 0     | 1     | 2             |
|       |           | 51-60      | 1     | 0     | 0     | 0     | 1             |
|       |           | Total      |       |       |       | 93    |               |




Fig :7: AGE-WISE DISTRIBUTION OF SEROTYPES

Table 8: MONTH-WISE DISTRIBUTION OF DENGUE POSITIVITY BY RT-PCR

| Sr.No | Months    | 2019-2020  | 2020-2021   |
|-------|-----------|------------|-------------|
| 1.    | January   | 0          | 2 (2.15%)   |
| 2.    | February  | 0          | 3 (3.22%)   |
| 3.    | March     | 0          | 2 (2.15%)   |
| 4.    | April     | 1 (6.67%)  | 5 (5.38%)   |
| 5.    | May       | 1 (6.67%)  | 6 (6.45%)   |
| 6.    | June      | 1 (6.67%)  | 5 (5.38%)   |
| 7.    | July      | 2 (13.33%) | 8 (8.60%)   |
| 8.    | August    | 2 (13.33%) | 12 (12.90%) |
| 9.    | September | 4 (26.66%) | 21 (22.58%) |
| 10.   | October   | 2 (13.33%) | 19 (20.43%) |
| 11.   | November  | 1(6.67%)   | 5 (5.38%)   |
| 12.   | December  | 1(6.67%)   | 5 (5.38%)   |
| 13.   | Total     | 15 (100%)  | 93 (100%)   |




Fig8: Month wise distribution of dengue positivity by RT-PCR

**DISCUSSION**

In the present study, out of total 283 suspected fever cases were subjected for the test NS1Ag ELISA of them, NS1Ag ELISA was found to be positive in 197 (69.61%) cases and 86 (30.39%) were negative. Our findings were similar to R. Ganesan et al (2019)<sup>3</sup> NS1 Ag was positive in 51.4% patients and Neelam Gupta et al (2019)<sup>4</sup> found positivity in 64.3%.

In the present study, out of total 197 NS1 ELISA positive cases were subjected for the test RT-PCR of them, RT-PCR was found to be positive in 108 (54.82%) cases and 89 (45.18%) were negative. Similar findings were reported by Tanmay K. Mehta (2009)<sup>5</sup>, that on the basis of RT-PCR, dengue infection was confirmed in 55.78% patients. Study done by Preeti Bharaj et al (2008)<sup>6</sup> reported 69.5% dengue positivity of RNA by RT-PCR.

In the table 3 In the present study, in the year 2019-2020, the most common serotype was found to be serotype DEN 1 followed by DEN 2 and DEN 3 while DEN 4 was not observed and in the year 2020-2021 DEN1 was found to be the most common serotype followed by DEN 2 but the serotype DEN 3 was completely replaced by DEN 4. Study done by Rubina Paul et al (2018)<sup>7</sup>, DENV-1 serotype was found in 57%, DENV-2 serotype was found in 3% and DENV-3 serotype was found in 40% DENV-4 serotype was not found in any sample.

Study done by BINITA JOSEPH ARING et al (2021)<sup>8</sup> found that Circulation of all the four serotypes, higher monotypic infection by DENV-1 serotype 41.2%, followed by DENV-4, DENV-2 and DENV-3. While study done by K. Alagarasu et al (2021)<sup>9</sup> found serotype DENV-2 was found to be the most common serotype in many states. Another study done by Shera Chaterji et al (2011)<sup>10</sup> found that DENV serotype, DENV-1 is 35.1%, DENV-2 is 29.9%, DENV-3 35.1%, DENV-4 is 0%. Rajesh NT et al (2017)<sup>11</sup>, Circulation of all the four serotypes of DENV has been reported from different regions of India. In 2017, DENV-1 and DENV-3 were more prevalent in Maharashtra, Western India. Persistent circulation of DENV-1 might have led to herd immunity permitting the emergence of other serotype viruses. Circulation of multiple serotypes suggests the hyperendemic nature of dengue in this region.

In the present study, out of total 108 dengue positive cases, 61(56.48%) were males and 47 (43.52%) were females. The ratio of Male to female was found to be 1.29 :1. Similar study done Rubina Paul et al(2018)<sup>7</sup> shows the higher prevalence of dengue infection was noted among males 64% than females 36%. The affected male to female ratio was 1.8:1. Nazish Parveen et al (2018)<sup>12</sup> also reported that more males were affected 53.57% as compared to females 33.33% with affected male/female ratio of 1.6:1. It might be due to differences in the socio-cultural environment where males are more exposed to outdoor activities and their bodies less covered as compared to females.<sup>13</sup>

In present study in both the consecutive year 2019-2020 and 2020-2021, male preprodance was found and the most common serotype was DEN 1 in the males than in the females. BINITA JOSEPH ARING et al (2021)<sup>8</sup> found that The ratio of male cases was higher than female, and in age group 21-35 year (47%) While the study done by Rishi Gowtham Racherla et al(2018)<sup>14</sup> found DENV-1 in 5.9% female and 6.7% male, DEN 2 in 29.4% female and 22.2% male. DEN 3 in 5.9% female and 8.9% male, DEN 4 in 19.6% female and 26.7% male.

Table no 6 shows that In the year 2019-2020, Out of total 15 dengue positive cases, maximum number of dengue positivity 9 (60%) was seen in the age group of 0-10 years, followed by 3 (20%) cases in the age group of 11-20 years, 2 (13.33%) were in the age group of 21-30 years, 1 (6.67%) were seen in 31-40 years, 0% cases above 50 years and above.

In the present study, in the year 2020-2021, Out of total 93 dengue positive cases, maximum number of dengue positivity 52 (55.92%) was seen in the age group of 21-30 years, followed by 24 (25.80%) cases in the age group of 0-10 years, 9 (9.68%) were in the age group of 11-20 years, 5 (5.37%) were seen in 31-40 years, 2 (2.16%) cases in 41-50 years. least no of positivity were seen above 60 years i.e.1 (1.07%) years.

Our findings are similar to Ekta Gupta et al (2006)<sup>15</sup> found that age group most commonly affected is 21-30 yrs followed by 0-10 years. Similar results were reported by Preeti Bharaj et al (2008)<sup>6</sup> were the maximum number of positivity were in the age group of 20-30 years (35.4%) followed by the age group 12-20 years (20.8%).

Nazish Parveen et al (2018)<sup>12</sup> found the maximum numbers of dengue positive cases 52.7% were found in the age group of 21-40 years followed by 0-20 years 33.3% cases respectively similiary Dr. Krishna Kumar Mani et al (2020)<sup>16</sup> observed more positivity of 30.90% in the age group 20 to 30 years followed by 10 to 20 years is 23.64% and 30 to 40 years is 21.82%. Rishi Gowtham Racherla et al (2018)<sup>14</sup> found that Adult age group was most affected amongst all the age groups This age group comprises working and student population. As dengue is mainly spread through Aedes mosquitoes which are day biters, the crowded areas such as workplaces and colleges may facilitate the spread of infection. Paediatric age group was next affected followed by geriatric age group.

Table no 7 shows: In the present study, in the year 2019-2020, serotype distribution, out of total 15 cases, 9 cases were in the age group of 0-10 years which includes, 1 cases of DEN 1, 7cases of DEN 2, 1 cases of DEN 3, 0 cases of DEN 4. 3 cases were in the age group of 11-20 years which includes, 1 cases of DEN 1, 1 cases of DEN 2, 1 cases of DEN 3, 0 cases of DEN 4. 2 cases were in the age group of 21-30 years which includes, 0 cases of DEN 1, 2 cases of DEN 2, 0 cases of DEN 3, 0 cases of DEN 4. 1 cases were in the age group of 31-40 years which includes, 1 cases of DEN 1, 0 cases of DEN 2, DEN 3 and DEN 4 and no cases were seen above 50 years and above.

In the year 2020-2021, serotype distribution, out of total 93 cases, 24 cases were in the age group of 0-10 years which includes, 15 cases of DEN 1, 9 cases of DEN 2, 0 cases of DEN 3 and DEN 4. 9 cases were in the age group of 11-20 years which includes, 3 cases of DEN 1, 5 cases of DEN 2, 0 cases of DEN 3, 1 cases of DEN 4. 52 cases were in the age group of 21-30 years which includes, 24 cases of DEN 1, 19 cases of DEN 2, 0 cases of DEN 3, 9 cases of DEN 4. 5 cases were in the age group of 31-40 years which includes, 4 cases of DEN 1, 0 cases of DEN 2, DEN 3 and 1 case of DEN 4. 2 cases were in the age group of 41-50 years which includes, 0 cases of DEN 1, 1 cases of DEN 2, 0 cases of DEN 3, 1 cases of DEN 4. 1 cases were in the age group of 51-60 years which includes, 1 cases of DEN 1 and 0 cases of DEN 2, DEN 3 and DEN 4 respectively.

Study done by Rishi Gowtham Racherla et al (2018)<sup>14</sup> found DENV-1 - 3% in ≤18 years of age group, 3% in 19-59 years, 0% in ≥60 years, DENV-2 - 16% in ≤18 years, 9% in 19-59 years and 0% in ≥60 years, DENV-3 - 1% in ≤18 years, 6% in 19-59 years and 0% in ≥60 years, DEN-4 - 8% in ≤18 years, 14% in 19-59 years and 0% in ≥60 years

In the present study, dengue positivity in the years 2019-2020 was found to be maximum in the month of September 2019-2020 i.e. 4 (26.66%) and maximum positivity in the years 2020-2021 was found to be in the month of September 21 (22.58%) followed by in October 19 (20.43%) and August 12 (12.90%). Similar findings were observed in the study done by Rubina Paul et al (2018)<sup>7</sup> that majority of cases tested positive for dengue were obtained in the month of September and October while study done by Vanlalhmingshanpui et al (2020)<sup>1</sup> found that majority of cases i.e. 19 (52.7%) were seen in the months of September to November 2017 (monsoon & post monsoon season).

## CONCLUSION

This study revealed the presence of four serotypes of dengue virus, with predominance of DENV-1 followed by DEN 2. This information on predominant circulating serotypes helps us in forecasting dengue outbreaks, which will certainly strengthen our ability and preparedness to address recurrent epidemics in this part of India. This should be concerns to public health authority and should stimulate the arbovirus diagnostic method in public health laboratories.

## REFERENCES

1. Vanlalhmingshanpui, Jayshree B. Bhakre, Jyoti A. Irvane, Ajit S. Damle and Pankaj A. Joshi. 2020. Prevalent Dengue Serotypes in and around Aurangabad, Maharashtra, India. *Int.J.Curr.Microbiol.App.Sci.* 9(11): 2186-2193. doi: <https://doi.org/10.20546/ijemas.2020.911.260>
2. Gowri Sankar S, Mowna Sundari T and Alwin Prem Anand A (2021) Emergence of Dengue 4 as Dominant Serotype During 2017 Outbreak in South India and Associated Cytokine Expression Profile. doi: 10.3389/fcimb.2021.681937
3. Ganesan, R., T. Sheila Doris Devamani and Joseph Pushpa Innocent, D. 2019. A Study on the Prevalence of Dengue Virus Infection using NS1 Antigen and IgM Antibody capture ELISA for the Early Diagnosis in and around Madurantakam. *Int.J.Curr.Microbiol.App.Sci.* 8(02): 1596-1600. doi: <https://doi.org/10.20546/ijemas.2019.802.187>
4. Gupta N, Bareja R, Diagnosis utility of various serological markers including NSI antigen for timely detection of dengue virus infection, *Int J Med Microbiol Trop Dis* 2019;5(1):37-4
5. Mehta TK, Shah PD. Identification of prevalent dengue serotypes by reverse transcriptase polymerase chain reaction and correlation with severity of dengue as per the recent World Health Organization classification (2009). *Indian J Med Microbiol* 2018;36:273-8
6. Preeti Bharaj1, Harendra S Chahar1, Anubhav Pandey1, Kavita Diddi1, Lalit Dar1, Randeep Guleria2, Sushil K Kabra3 and Shobha Broor, Concurrent infections by all four dengue virus serotypes during an outbreak of dengue in 2006 in Delhi, India, Published: 9 January 2008 *Virology Journal* 2008, 5:1 doi:10.1186/1743-422X-5-1 Received: 23 July 2007, Accepted: 9 January 2008
7. Rubina Paul1, Loveena Oberoi2, Kanwardeep Singh3, Pushpa Devi4, Molecular Characterization and Serological Analysis of Dengue Viruses in Amritsar District, Volume 5 | Issue 3 | March 2018 | ICV: 77.83 | ISSN (Online): 2393-915X; (Print): 2454-7379
8. Binita Joseph Aring1, Dipali Maganbhai Gavali2, Pushpa Ramjibhai Kateshiya3, Hiral Modbhai Gadhi4, Summaiya Mullan5, Kamaxi Kirithbhai Trivedi6, Akhlakhahamad Alihbhai Nathametha7, Anand Hitenbhai Nakhava8 Co-circulation Of All The Four Serotypes Of Dengue Virus In Endemic Region Of Saurashtra, Gujarat During 2019-2020 Season, Doi: 10.7860/jcdr/2021/49300.15065 Original Article Microbiology
9. K. Alagarasu a, □, J.A. Patil a, M.B. Kakade a, A.M. More a, B. Yogesh a, P. Newase a, S.M. Jadhava a, D. Parashara, H. Kaur b, N. Gupta b, N. Vijay b, J. Narayan b, P.S. Shah a, On behalf of VRDL Team, Serotype and genotype diversity of dengue viruses circulating in India: a multi-centre retrospective study involving the Virus Research Diagnostic Laboratory Network in 2018, *International Journal of Infectious Diseases* 111 (2021) 242–252, article, Received 14 June 2021 Revised 18 August 2021
10. Shera Chaterji, John Carson Allen Jr., Angelia Chow, Yee-Sin Leo, and Eng-Eong Ooi, Evaluation of the NS1 Rapid Test and the WHO Dengue Classification Schemes for Use as Bedside Diagnosis of Acute Dengue Fever in Adults, *Am. J. Trop. Med. Hyg.*, 84(2), 2011, pp. 224–228 doi:10.4269/ajtmh.2011.10-0316 Copyright © 2011 by The American Society of Tropical Medicine and Hygien.
11. Rajesh Nt1\*, Alagarasu K2\*, Patil JA2, Bharathi E1, More A2, Kakade MB2, Merlin Veronika1, Jothilakshmi K1, Shah PS, Serotype specific differences in the laboratory parameters among hospitalized children with dengue and genetic diversity of dengue viruses circulating in Tamil Nadu, India during 2017, doi: 10.1002/jmv.25639.
12. Nazish Parveena, Arshi Islama, Ayesha Tazeena, Malik Hisamuddinab, Mohd Abdullaha,b, Irshad H. Naqvic, Md I. Faizana, Divya Gulyania, Anwar Ahmedde, Shama Parveena, Circulation of single serotype of Dengue Virus (DENV-3) in New

Delhi, India during 2016: A change in the epidemiological trend, Received 2 November 2017 Received in revised form 20 July 2018 Accepted 27 August 2018, <https://doi.org/10.1016/j.jiph.2018.08.008>

13. Madkey MV, Gedam DS, Meshram VM, Gajbhiye SB. Seroprevalence of dengue in the tribal district of central India. *Indian J Microbiol Res* 2021;8(1):45-48.
14. Racherla RG, Pamireddy ML, Mohan A, Mudhigeti N, Mahalakshmi PA, Nallapireddy U, et al. Co-circulation of four dengue serotypes at South Eastern Andhra Pradesh, India: A prospective study. *Indian J Med Microbiol* 2018;36:236-40.
15. Ekta Gupta, Lalit Dar, Geetanjali Kapoor and Shobha Broor\*, The changing epidemiology of dengue in Delhi, India, *Virology Journal* 2006, 3:92 Address: Department of Microbiology, All India Institute of Medical Sciences, New Delhi-110029, India
16. Dr. Krishna Kumar Mani1, Dr. Abhimanyu Kumar Singh2, Dr. Kumar Amresh3, Dr. Ranjan Kumar4, Role of IgM antibody capture ELISA for the early diagnosis of dengue viral infection- Prospective observational study, *European Journal of Molecular & Clinical Medicine (EJMCM)* ISSN: 2515-8260 Volume 07, Issue 11, 2020